Posted by Michael Wonder on 08 May 2026
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
7 May 2026 - The MHRA has today approved donidalorsen (Dawnzera) for use in patients 12 years and older with hereditary angioedema to prevent angioedema attacks.
This product was submitted and approved via International Recognition Procedure.
